These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Letter: Corynebacterium parvum and anaesthetics. Mosedale B; Smith MA Lancet; 1975 Jan; 1(7899):168. PubMed ID: 46085 [No Abstract] [Full Text] [Related]
4. Toxicity of IL-2 and Corynebacterium parvum following direct intracranial injection. Sutton RC; Kennedy J; Duncan J; Conley FK J Neurooncol; 1989 Sep; 7(3):261-7. PubMed ID: 2795120 [TBL] [Abstract][Full Text] [Related]
5. Organ distribution of Corynebacterium parvum labeled with iodine-125. Dimitrov NV; Greenberg CS; Denny T J Natl Cancer Inst; 1977 Feb; 58(2):287-94. PubMed ID: 833877 [TBL] [Abstract][Full Text] [Related]
6. [Preliminary considerations on the intravenous use of Corynebacterium parvum in the treatment of solid neoplasms]. Scheinberg MA; Sartori JP; de Pinho JG AMB Rev Assoc Med Bras; 1979 Apr; 25(4):139-40. PubMed ID: 315598 [No Abstract] [Full Text] [Related]
7. The effects of Corynebacterium parvum in dogs and a study of its distribution following intravenous injection. Owen LN; Lewis JC; Morgan DR; Gorman NT Eur J Cancer (1965); 1980 Aug; 16(8):999-1005. PubMed ID: 6777166 [No Abstract] [Full Text] [Related]
8. A comparison of the toxicity of two formulations of Corynebacterium parvum in a double-blind crossover trial in patients with bronchogenic carcinoma. Mitcheson HD; Priestman TJ Clin Oncol; 1981 Sep; 7(3):179-82. PubMed ID: 7044635 [No Abstract] [Full Text] [Related]
9. Proliferative glomerulonephritis in mice given intravenous Corynebacterium parvum. Uff JS; Mitcheson HD; Pussell BA; Brill M; Castro JE J Pathol; 1981 Feb; 133(2):89-105. PubMed ID: 6451676 [TBL] [Abstract][Full Text] [Related]
10. Lung cancer patients treated with Corynebacterium parvum. Phase I toxicity study. Yadeau R; Bates HA; Fortuny I Minn Med; 1979 Sep; 62(9):673-5. PubMed ID: 503003 [No Abstract] [Full Text] [Related]
12. Metabolic changes following the intravenous infusion of Corynebacterium parvum in man. Royle G; Gill PG Cancer; 1979 Apr; 43(4):1328-30. PubMed ID: 445333 [TBL] [Abstract][Full Text] [Related]
13. Proceedings: Immunotherapy of Moloney sarcoma virus tumours in mice with Corynebacterium parvum. Hamilton DN; Bell PR Br J Surg; 1974 Apr; 61(4):321. PubMed ID: 4832648 [No Abstract] [Full Text] [Related]
14. Chemoimmunotherapy (DTIC and Corynebacterium parvum) for disseminated malignant melanoma. Karakousis CP; Didolkar MS; Han T Cancer Treat Rep; 1981; 65(9-10):925-6. PubMed ID: 7273032 [No Abstract] [Full Text] [Related]
15. [Treatment of neoplastic pleural effusion by intrapleural administration of Corynebacterium parvum vaccine]. Krasucka-Kluźniak A; Krakówka P Pneumonol Pol; 1985 May; 53(5):240-7. PubMed ID: 4047949 [No Abstract] [Full Text] [Related]
16. Editorial: Immunological control of cancer. Lancet; 1975 Mar; 1(7905):502-3. PubMed ID: 46965 [No Abstract] [Full Text] [Related]
17. Phase I study of corynebacterium parvum in patients with solid tumors. Band PR; Jao-King C; Urtasun RC; Haraphongse M Cancer Chemother Rep; 1975; 59(6):1139-45. PubMed ID: 769953 [TBL] [Abstract][Full Text] [Related]
18. Lack of immunological and anti-tumour effects of orally administered Corynebacterium papvum in mice. Sadler TE; Castro JE Br J Cancer; 1975 Mar; 31(3):359-63. PubMed ID: 1156520 [No Abstract] [Full Text] [Related]